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abstract
Cancer Informatics for Cancer Centers (CI4CC) is a grassroots, nonproﬁt 501c3 organization intended to provide
a focused national forum for engagement of senior cancer informatics leaders, primarily aimed at academic
cancer centers anywhere in the world but with a special emphasis on the 70 National Cancer Institute–funded
cancer centers. Although each of the participating cancer centers is structured differently, and leaders’ titles
vary, we know ﬁrsthand there are similarities in both the issues we face and the solutions we achieve. As
a consortium, we have initiated a dedicated listserv, an open-initiatives program, and targeted biannual face-to-
facemeetings. Thesemeetings are a place to review our priorities and initiatives, providing a forum for discussion
of the strategic and pragmatic issues we, as informatics leaders, individually face at our respective institutions
and cancer centers. Here we provide a brief history of the CI4CC organization and meeting highlights from the
latest CI4CC meeting that took place in Napa, California from October 14-16, 2019. The focus of this meeting
was “intersections between informatics, data science, and population science.”We conclude with a discussion
on “hot topics” on the horizon for cancer informatics.
JCO Clin Cancer Inform 4:108-116. © 2020 by American Society of Clinical Oncology
INTRODUCTION
Brief History of Cancer Informatics for
Cancer Centers
Cancer Informatics for Cancer Centers (CI4CC) is
a grassroots, nonproﬁt 501c3 organization intended to
provide a focused national forum for engagement of
senior cancer informatics leaders, primarily aimed at
academic cancer centers anywhere in the world but
with a special emphasis on the 70 National Cancer
Institute (NCI)–funded cancer centers (https://www.
ci4cc.org). CI4CC started as an attempt to maintain the
sense of community and comradery that the NCI
cancer Biomedical Informatics Grid—caBIG—program
had developed, as that program was winding down in
2012. We held our ﬁrst meeting in Dallas, Texas, in
February of 2013. That meeting, attended by repre-
sentatives of approximately 30 of the NCI-designated
cancer centers, was testing the waters to see if such an
event was needed and if the cancer informatics
community was receptive and willing to participate. At
that meeting, we had all the cancer informatics cores
describe their structure, funding methodology (typi-
cally direct charge or effort on grants), and strategy for
embedding informatics (and “data science”) in their
cancer center. On the basis of the positive feedback
from that initial meeting, we started meeting twice
annually, with the next meeting in November of 2013
in the Bay Area of California. A preponderance of our
meetings have been held in California, with only the
meetings in Dallas, Washington DC, Park City, New
Orleans, and Maui outside of California. Every meeting
has had a different focus, most meetings have had two
chairs, and many meetings have included aspects of
precision oncology and how we can support precision
oncology and learning health systems for cancer more
effectively using informatics, data science, and ma-
chine learning (ML) approaches. It is important to
foster diversity, with the goal of welcoming all members
of the cancer informatics community and including
them in CI4CC. CI4CC has been fortunate to have
featured presentations from two NCI Directors, Drs
Harold Varmus and Ned Sharpless. We have a “di-
rectors circle,” featuring cancer center directors,
deputy directors, and NCI directors who have spoken
at one or more CI4CC events (http://www.ci4cc.org/
events/directors-circle). In addition to precision
medicine, we have had meeting topics ranging from
how informatics, data science, and ML can be applied
to research problems in population health, pediatrics,
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cancer clinical trials, cancer registries, molecular tumor
boards, and cancer surveillance.
THE FALL 2019 CI4CC MEETING
The biannual face-to-face conferences often focus on
a particular theme, providing an opportunity for members of
the informatics community to interact with leaders in re-
lated scientiﬁc disciplines to foster multidisciplinary ap-
proaches to cancer research and care delivery. Although
we do not explicitly focus on team science, the ability of
each of our member centers to successfully solve problems
in any of these areas requires building interdisciplinary
teams and using team science approaches.
For the Fall 2019 conference, we focused on the integration
of data science and informatics with population science,
highlighting scientiﬁc advances and ongoing efforts to
better understand cancer etiology, identifying new ap-
proaches for cancer prevention and early detection, im-
proving outcomes for patients with cancer, and enhancing
cancer care delivery throughout the community. Data
collection and analysis have continuously evolved within
the context of population science studies, increasingly
incorporating digital tools for assessment of exposures and
health behaviors. Furthermore, as we seek to unravel the
complexity of cancer, novel informatics and data science
approaches are required to integrate and analyze data
across multiple biologic scales, including genomics, pa-
thology, and radiology-based images and clinical and
patient-reported outcomes. Given the complexity and
amount of data currently available on patients with cancer
and populations at risk for cancer, further convergence of
data and population sciences is required to effectively
advance data capture, integration, and analysis, with the
common goal of reducing the cancer disease burden in the
population. The Fall 2019 CI4CC conference covered
topics such as collection of cancer risk factor information
and outcomes through digital tools, data science ap-
proaches for advancing insights from cohort and other
large-scale population-based studies, data linkages for
catchment area research, strategic approaches to creating
and maintaining electronic data warehouses for the ad-
vancement of cancer research and care delivery (including
common data models), leveraging artiﬁcial intelligence (AI)
for observational research, and evolving Cancer Center
Support Grant (CCSG) cores to support optimal data ac-
cess, integration, and analysis. Below we provide meeting
highlights from the CI4CC meeting that took place in Napa,
California from October 14-16, 2019.
HIGHLIGHTS FROM THE FALL 2019 CI4CC MEETING
Day 1
Drs Jill Barnholtz-Sloan (Case Western Reserve University
School of Medicine and University Hospitals of Cleveland)
and Dana Rollison (Mofﬁtt Cancer Center), the conference
co-chairs, set the stage for the conference by providing an
overview of how data science, informatics, and population
science intersect in a variety of areas of cancer research
(Fig 1). Many large-scale cancer epidemiology cohort
studies are recognizing the importance of leveraging state-
of-the-art informatics and data science approaches to
enhance data collection and promote data sharing. In-
formatics and data science approaches are also being used
to model cancer biology across scales, including genomics,
pathology, and radiology. Population-based cancer regis-
tries are using informatics approaches to augment in-
formation available in the registry with rich data available in
other publicly available datasets. Finally, ML techniques are
beginning to be leveraged by population-based datasets
CONTEXT
Key Objective
How best do we share ideas and best practices in the cancer center community in the informatics domain? Through the
Cancer Informatics for Cancer Centers (CI4CC) organization, we enable cancer centers to explore and learn from
each other.
Knowledge Generated
Cancer informatics is an ever-growing and diverse ﬁeld. We focused the Fall 2019 meeting on the integration of data science
and informatics with population science. Topics covered included: collection of cancer risk factor information and out-
comes through digital tools, data science approaches for advancing insights from cohort and other large-scale population-
based studies, data linkages for catchment area research, strategic approaches to creating andmaintaining electronic data
warehouses for the advancement of cancer research and care delivery (including common data models), leveraging
artiﬁcial intelligence for observational research, and evolving Cancer Center Support Grant cores to support optimal data
access, integration, and analysis.
Relevance
Through the Fall CI4CC meeting we were able to highlight scientiﬁc advances and ongoing efforts to better understand cancer
etiology, identifying new approaches for cancer prevention and early detection, improving outcomes for patients with
cancer, and enhancing cancer care delivery throughout the community.
Cancer Informatics for Cancer Centers (CI4CC) 2019 Meeting
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and cohort studies. The sessions of the conference focused
on each of these intersections, and selected highlights from
each session are described below.
Population-based data collection for cancer prevention and
care delivery. This ﬁrst session highlighted large-scale,
population-based initiatives that leverage informatics tools
to understand patterns in cancer incidence, treatment,
survival, and related factors. Ms LisaMirel from theNational
Center for Health Statistics (NCHS) Data Linkage Program
described how information collected through the NCHS
population-based health surveys, such as the National
Health and Interview Survey (NHIS) and the National
Health and Nutrition Examination Survey (NHANES), are
linked to vital and administrative data from other sources
(National Death Index, Centers for Medicare & Medicaid
Services enrollment and claims data, Department of
Housing and Urban Development data on housing assis-
tance), and discussed the informatics-related method-
ologies that enable use of the linked ﬁles (https://www.
cdc.gov/nchs/data-linkage/index.htm). This program is
designed to maximize the scientiﬁc value of the Center’s
population-based surveys and enable researchers to ex-
amine the factors that inﬂuence disability, chronic disease,
health care utilization, morbidity, and mortality. The linked
ﬁles expand the analytic potential of both the survey and
administrative data, enabling analyses that would not be
possible with either data source alone. For example, linked
ﬁles have been used to address a variety of cancer-related
research topics, including the association between muscle-
strengthening physical activity and cancer mortality, as well
as the association between folate intake and biomarkers
and cancer risk.1,2 The Data Linkage Program releases two
types of public-use ﬁles: (1) public-use linked mortality
ﬁles, containing a limited set of variables; and (2) feasibility
ﬁles, designed to help interested researchers determine the
maximum available sample sizes and assess the feasibility
of analyses using the restricted-use linked ﬁles. To protect
conﬁdentiality of survey participants, all the other linked
data ﬁles are restricted use and can be accessed only
through the NCHS Research Data Centers (NCHS Re-
search Data Center: https://www.cdc.gov/rdc/index.htm).
Dr Marta Induni from the Cancer Registry of Greater Cal-
ifornia (CRGC) spoke about informatics advances facilitating
rapid reporting of pathology reports in a standard format, in
compliance with California’s new law requiring pathologists
to report cancer cases within 2 weeks (AB 2325; (https://
leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=
201520160AB2325). This accelerated and structured
reporting allows a central cancer registry to become more
relevant to patients with active disease and can facilitate
near–real-time use of cancer data to beneﬁt the quality of
life (QoL) and improve outcomes for patients with cancer
in its catchment. Several use cases were presented from
CRGC, including a proposed alert system for pathologists
who do not follow best practices, standards of care, or
standard operating procedures. The College of American
Pathologists encourages structured reporting of required
data elements for the purpose of interoperability, data
capture, and data exchange (https://documents.cap.org/
protocols/dSynoptic_Report_DeﬁnitionAndExamples_v4.0.
pdf). Furthermore, this rapid reporting to centralized
registries could facilitate the matching of eligible patients
to clinical trials soon after initial diagnosis.
Dr Elizabeth Shenkman from the University of Florida fo-
cused her talk on novel approaches for leveraging real-
world data points from electronic health records, health
Informatics
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Population-
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pharmacosurveillance, patient-reported outcomes)
Multiscale data
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Capitalizing on large-scale cancer epidemiology cohorts
using informatics and data science approaches
‘’Intersections’’ at CI4CC Fall 2019 Conference
FIG 1. Intersections between pop-
ulation science, data science, and
informatics highlighted at the Can-
cer Informatics for Cancer Centers
Fall 2019 conference.
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care claims, patient report, and other sources to generate
evidence about cancer-related outcomes for diverse pa-
tient populations, including those that may be under-
represented in biomedical research.3 Such approaches
for cancer control include: (1) incorporation and linking of
contextual data, such as census tract and environmental
information, to real-world health data; and (2) use of diverse
computational and statistical modeling techniques.4 The
OneFlorida Clinical Research Consortium was created to
form an enduring infrastructure for cohort discovery, prag-
matic clinical trials, and observational studies.5 A hallmark of
OneFlorida is its centralized Data Trust, which contains linked
electronic health record, tumor registry, claims, and geospatial
data for . 14 million Floridians. Currently, 24 cancer-related
studies are being conducted in OneFlorida (examples are:
https://maps.cancer.gov/overview/DCCPSGrants/abstract.jsp?
applId=9816491&term=CA234030; and https://www.pcori.
org/research-results/2019/natural-language-processing-
connect-social-determinants-and-clinical-factors). This state-
wide approach to cancer prevention can be used as a model
for other states or large regions of the country.
Novel ML/AI approaches to observational studies. This
second session focused on state-of-the-art data science
approaches to the analysis of observational data, with
speakers presenting examples in genomics, pharmaco-
surveillance, and patient-reported outcomes (PROs), the
latter of which was the focus of the presentation by Dr
Amrita Basu from the University of California, San Fran-
cisco. PROs may be used to measure QoL, a topic of in-
creasing importance to women diagnosed with breast
cancer who often experience some form of drug-related
toxicity, psychosocial distress, and subsequent impair-
ments in their QoL. Impairments in QoL can interfere with
treatment adherence and engagement in health-promoting
behaviors, whereas effective management of symptoms
during treatment has been associated with improved QoL,
adherence, and increased survival. Dr Basu discussed the
development of the neoadjuvant Clinical Beneﬁt Index,
a novel longitudinal approach to assessing QoL in breast
oncology that provides a single numerical index of QoL and
clinical efﬁcacy, and went on to describe the impact of age,
stage, and educational status on QoL in a separate study of
patients with breast cancer enrolled in the California Athena
Breast Cancer Study, where impaired QoL in one domain
was associated with more severe symptoms in another.
These insights may lead to strategies to prevent or delay
symptom onset or interference, promote intervention at the
earliest detectable onset of symptoms, and result in sup-
portive care and treatment adaptations.
Paul fearn memorial lecture and poster session. Day 1
wrapped up with the Paul Fearn Memorial Lecture and
Poster Session. Dr Paul Fearn was a respected leader in
cancer informatics. He contributed to the ﬁeld not only
through his vast technical expertise but also through
a powerful combination of creative strategy, innovative
approaches, insightful empathy, and a passion for training
the next generation of informatics professionals. He pro-
vided steadfast guidance and support not only to his team
but also to many he encountered, promoting innovation
and openness among colleagues across ﬁelds. The CI4CC
community aimed to honor Dr Fearn’s legacy through the
Inaugural Paul FearnMemorial Lecture and Poster Session.
Nine CI4CC investigators presented their work as part of
these events in honor of Dr Fearn, including Dr Jack
DiGiovanna from Seven Bridges, who discussed leveraging
cloud-based analysis ecosystems to support training
the next generation of data scientists. The National In-
stitutes of Health (NIH) Strategic Plan for Data Science
includes expanding the national research workforce and
collaboration across disciplines as key objectives (https://
datascience.nih.gov/strategicplan). However, training bio-
medical scientists with diverse backgrounds on essential,
complex, and iterative data science techniques is chal-
lenging. Once data scientists have the appropriate theo-
retical background, applying it to real-world research
questions has an additional learning curve. For example,
there are multiple hurdles associated with accessing
controlled datasets, exploring them, and understanding
them sufﬁciently to investigate relevant questions. A ﬁnal
obstacle is adequate “hands-on” training with scientiﬁc
analysis software. To tackle these challenges, the Seven
Bridges team leveraged three data ecosystems: the NCI
Cancer Research Data Common (CRDC) Cancer Genomics
Cloud,6 the NHLBI BioData Catalyst, and the NIH Common
Fund Gabriella Miller Kids First DRC’s Cavatica (https://
kidsﬁrstdrc.org/). Diverse trainees were successfully con-
nected to actionable data in collaborative, powerful, and
cost-efﬁcient environments. Representative examples span
high school students visualizing gene expression levels to
graduate student geneticists learning to code association
studies. Leveraging cloud-based analysis ecosystems could
provide an important component of training the national
research workforce.
Day 2
The second day continued the conference theme by
starting with presentations and a panel discussion focused
on ongoing large-scale epidemiologic cohort studies that
are leveraging data science and informatics to advance the
generation of new knowledge. These studies are essential
components of the cancer research enterprise, providing
ideal settings for assessing how real-world data affect
cancer risks and outcomes.
Cancer cohorts and other large-scale population studies: the
importance of data science and informatics. Dr Montserrat
Garcia-Closas from the NCI described NCI-Connect, a new,
prospective cohort study being conducted by investigators
in the NCI Division of Cancer Epidemiology and Genetics
(DCEG) in collaboration with integrated health care systems
in the United States. The primary aim is to build a com-
prehensive research resource using new technologies and
Cancer Informatics for Cancer Centers (CI4CC) 2019 Meeting
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methods for the scientiﬁc community to study cancer eti-
ology, precursor to tumor transformation, cancer risk
prediction, early detection of cancer, and second cancers
and cancer survivorship. To this end, the cohort is designed
to enroll up to 200,000 adults free of cancer for long-term
follow-up with serial data and biospecimen collections,
following rigorous epidemiologic principles. Data will be
collected by multiple mechanisms, including question-
naires, electronic health care records (EHRs), medical
images, mobile and wearable technologies, and data
linkages to resources such as cancer and mortality regis-
tries and environmental-monitoring data. Biospecimens will
be used to generate data on biomarkers of susceptibility,
internal dose, and early biologic effects using targeted and
-omic technologies. NCI-Connect is being designed using
an information technology system’s architecture to support
a mobile app for participant engagement and data col-
lection to supporting big data analytics by scientists, all
while facilitating reproducible dissemination in the public
domain. This infrastructure will enable Epidemiology Data
Commons (the colocation of data assets and code in the
cloud) to facilitate following of the Findable, Accessible,
Interoperable, Reusable (FAIR) principles for scientiﬁc data
management and stewardship.7 To achieve these goals,
DCEG is developing a serverless cloud execution model
facilitated by resources available through the NIH Science
and Technology Research Infrastructure for Discovery,
Experimentation, and Sustainability—STRIDES—program
(https://datascience.nih.gov/strides). The key design mo-
tivations for this data system are: (1) interoperability:
decoupling of the data layer from the application layer by
stateless application programming interfaces (APIs); (2)
user-centric governance at the service (API call) layer level:
this model is a far safer than “security at the perimeter,”
and maximizes collaborative use and data analysis, be-
cause usages are associated with the identity and scope
of the user making the API call to the data service; (3)
delivery of cloud-based, consumer-facing Web apps: the
API ecosystem acts as a “marketplace” for pluggable
components. The investigators expect that a broader cohort
commons infrastructure will eventually emerge, maybe
under the aggregation of other resources, such as the NIH
All of Us program.
Dr Alexander Borowsky from University of California, Davis,
provided an overview of the NIH All of Us Program, which
aims to build an ambitious and unprecedented longitudinal
cohort of 1 million persons, representative of the population
of the United States,8 including demographic subgroups
that are underrepresented in current and past biomedical
research, deﬁned by race, ethnicity, age, sex, gender
identity, sexual orientation, disability status, access to
health care, income, education level, and/or geographic
location.9 Participants agree to provide access to their
medical records, to complete survey questionnaires, and to
provide blood (or saliva) and urine samples. Participants
are provided permanent access through a password-
protected web portal and smart phone app to review de-
tails of their own data, to refresh or add to questionnaire
data, to link wearable ﬁtness tracker data, and to see ag-
gregated information about the overall cohort. To achieve
the goals of the study, multiple critical informatics systems
with connections were developed.10 The participant portal
serves as the initial enrollment tool, serving video de-
scriptions of the purpose and speciﬁc consent elements of
the program, as well as handling the informed consent
documentation with e-signature. This portal was designed
to recognize the state of residence/enrollment of the par-
ticipant to serve state-speciﬁc information and documents
to comply with state as well as federal health information
and research consent regulations. Enrollment on the portal
is monitored by the system with location-based information
transmitted to the appropriate health care provider partners
or “direct volunteer” enrollment sites. After enrollment and
collection of biospecimens, the participant electronic
medical record data are mapped to a common data model
Observational Medical Outcomes Partnership (OMOP) and
securely transmitted quarterly to the central database.
Dr James Lacey Jr fromCity of Hope shared lessons learned
from modernizing an existing epidemiology cohort study to
be compatible with the NCI’s CRDC and the principles of
FAIR data. Since 2015, the California Teachers Study (CTS;
www.calteachersstudy.org/for-researchers), which began
in 1995-1996 and has followed . 133,000 women con-
tinuously since, has replaced its legacymethods with a data
warehouse, a secure remote desktop, and standardized
processes conﬁgured for population sciences. Data visu-
alizations, reusable workﬂows, and analytic tools provide
scalability, and the environment meets the technical re-
quirements of the CRDC. As the CTS has deployed these
tools, a consistent challenge has emerged: how can co-
horts like the CTS present their vast data in ways that
enable users to perform the complex, individualized, and
unpredictable analyses that epitomize epidemiologic re-
search? The CTS includes . 5,000 columns of patient-
reported data, 30,000 cancers and 30,000 deaths, and
500,000 hospitalization end points, but most projects make
their “go v no-go” decisions on the basis of only a handful of
data points. Epidemiology data commons need to make all
of their data available and provide user-friendly query and
analytic tools that allow users to deﬁne as many combi-
nations as possible and capitalize on the complexity that
makes cancer cohorts valuable.
Multiscale data integration for cancer discovery. The
second session on Day 2 focused on the complexities of
analyzing data across scales, including genomics, patho-
mics, and radiomics. As our understanding of cancer bi-
ology deepens within each of these scales, development of
quantitative approaches for integrating information across
scales will be increasingly important for convergence
research.
Barnholtz-Sloan et al
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Dr Joel Saltz from Stonybrook University discussed the
evolution of his team’s work to develop digital pathology
ML/AI whole-slide image methodologies.11 Their focus has
been on developing methods for using routinely collected
biopsy and excision specimens to generate pathophysi-
ological ground truth for large-scale clinical investigations
to improve clinical workﬂows and thereby affect patient
care. The methodologies encompass ML/deep learning
methods, software for viewing whole-slide images and
annotations, and data management methods for digital
pathology analytic algorithm results.12 They coined the
term “pathomics” to describe digital pathology in-
formation; this includes segmented cell nuclei, maps of
tumors and inﬁltrating lymphocytes, and features di-
rectly extracted from digital pathology images using AI
algorithms.13
Dr Jennifer Permuth from Mofﬁtt Cancer Center discussed
approaches to analyzing radiologic images and genomics
(“radiogenomics”) in the context of pancreatic cancer
(PaCa) and its precursors. Intraductal papillary mucinous
neoplasms (IPMNs) are the most common cystic pre-
cursors to PaCa, the only solid malignancy with a 5-year
relative survival rate , 10%.14,15 To date, existing imaging
modalities and molecular markers cannot reliably distin-
guish low/moderate grade (benign) IPMNs that merit
surveillance from high-grade/invasive (malignant) IPMNs
that warrant surgical resection, posing a great clinical
challenge.14 By leveraging expertise in population, clinical,
and data science and informatics and multi-institutional
infrastructure known as the Florida Pancreas Collaborative,16
the team seeks to discover a combined quantitative
imaging and biomarker approach that is noninvasive and
has added value in predicting IPMN pathology beyond
that provided by standard radiologic and clinical char-
acteristics. The team will build on their preliminary studies
to evaluate underexplored categories of quantitative
“radiomic” features extracted from preoperative com-
puted tomography scans,17,18 along with a circulating
plasma microRNA blood test that they have developed,18
and generate prototype clinical decision-making models
(nomograms) to predict malignant IPMN pathology. They
will also evaluate the relationship between radiomic fea-
tures and biologic processes characterized by microRNA
and/or mucin expression that underlie IPMN tumor de-
velopment and/or progression to glean diagnostic and
prognostic information. This line of translational research
has potential to foster clinically actionable information
that may be used to rapidly and cost effectively person-
alize care for individuals with IPMNs and reduce PaCa
burden.
Dr Alex Bui from the University of California, Los Angeles
discussed challenges and opportunities for data integration
against the backdrop of the increasing volume and variety
of biomedical and clinical big data, such as -omics, im-
aging, EHRs, and mHealth. The potential of using these
data with new computational methods like ML to advance
our understanding of cancer and its treatment is driving
signiﬁcant excitement. But harnessing this information
requires facing two challenges: combining such data to
support comprehensive analyses, and ensuring that the
data used are appropriate to inform real-world applications.
First, often each type of data is analyzed in isolation,
thereby missing an opportunity to view the disease as
a phenomenon seen across spatial scales (eg, from the
molecular to the person) and time (eg, from screening and
diagnosis through to treatment and survivorship). For ex-
ample, crossover areas like radiogenomics frequently
consider features separately (ie, radiomics, genomics)
before combining them, when joint analyses may proffer
different results. Increased computational power and novel
algorithms for automated knowledge graph construction
can help make these connections over large observational
datasets. Second, integration is itself insufﬁcient, as the
nature and quality of the data used in downstream analyses
must be considered. Indeed, the (clinical) applicability of
a model developed using ML is contingent on its ability to
work with real-world data, given inherent noise, missing
data, and bias. Moreover, as the environment in which
an ML model is deployed changes (eg, new technologies
or therapies), it may become outdated. Infrastructure for
continual data curation and performance re-evaluation of
data-driven analyses are thus necessary, and how these
models evolve can guide future insights about cancer
outcomes and research directions.
Day 2 of the Fall 2019 meeting concluded with a panel
discussion on data integration and availability through
CCSG cores. Dr Jeanine Genkinger from Columbia Uni-
versity discussed that different models exist for cancer
center shared resources that are designed to develop and
support studies to address and promote clinically relevant
and innovative research. Starting in 2014, the DataBase
Shared Resource (DBSR) at the Columbia University
Herbert Irving Comprehensive Cancer Center was tasked
to develop, integrate, and maintain a centralized, cost-
effective, and well-characterized research database. As
such, the DBSR has: (1) integrated all prior adult solid
tumor registries into one standardized protocol, (2) created
a retrospective cohort of patients through linkage of data
from EHRs across multiple platforms and data warehouses
(ie, New York-Presbyterian Hospital [NYPH] Tumor Reg-
istry) with existing residual tissue samples, and (3) de-
veloped and maintained a prospective cohort implemented
through a standardized protocol with universal consent of
individuals with cancer or at risk for cancer, collecting
biospecimens and epidemiologic data, and linking to data
from the EHR/NYPH Tumor Registry and residual tissue
samples. To date, DBSR integrated 24 clinical registries
into one overarching research database. Because of highly
qualiﬁed and bilingual recruiters, DBSR has met its accrual
targets and enrolled. 4,700 individuals, fromwhomDBSR
Cancer Informatics for Cancer Centers (CI4CC) 2019 Meeting
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has collected . 2,400 biospecimens and . 2,600 ques-
tionnaires. To foster research, the DBSR has approved and
fulﬁlled . 120 data and biospecimen requests and sup-
ported . 10 ancillary studies through efﬁcient enrollment
and data extraction. Through this, the DBSR has supported
several federally funded grants and peer-reviewed
publications.
Dr Wenjin (Jim) Zheng from the University of Texas Health
Science Center at Houston discussed his vision for pro-
active, data-driven cancer informatics support, whereby
data analysts in the informatics core can take a lead role
with data analysis and mining to make discoveries or
generate hypotheses and work together with experimen-
talists and clinician to drive cancer research. A successful
proactive informatics core needs several critical compo-
nents. First, informaticians should have broad knowledge of
cancer research so that they can initiate scientiﬁcally sound
projects or work with experimentalists and clinicians to
do so.20 Second, sufﬁcient ﬁnancial support should be in
place so informaticians can afford the high-risk and time-
consuming nature of exploratory projects. Third, there
should be open-minded experimental or clinical collabo-
rators who are willing to embrace data-driven research. Last
but not least, there should be a robust computing in-
frastructure that allows quick, prototypical, and exploratory
analysis of a large amount of data to generate sufﬁcient
results to initiate new projects or to make signiﬁcant con-
tributions to existing projects. Satisfying these conditions
can ensure a cancer informatics core support that is highly
productive and impactful.
Dr Travis Gerke from Mofﬁtt Cancer Center discussed the
Collaborative Data Services Core (CDSC), which provides
access to the Center’s robust data assets. Discrete data on
. 570,000 patients are available through an enterprise-
wide data warehouse, which spans clinical, administrative,
patient-reported, biospecimen, and molecular domains.
CDSC provides three primary services: (1) study design
consultations, which feature cohort identiﬁcation and as-
sess feasibility; (2) provisioning of patient data from source
systems, often complemented by a manual medical record
abstraction service for information not available in discrete
format; and (3) individual or small-group training on self-
service querying tools and best practices. A high volume of
service requests (400-500 annually) are fulﬁlled on an
hourly chargeback system by a team of 8 data scientists, 6
database abstractors, and 6 operational team members.
Day 3
Day 3 featured a Cancer Center Directors Keynote Lecture
from Dr Cornelia Ulrich, Executive Director of the Com-
prehensive Cancer Center at Huntsman Cancer Institute
(HCI). HCI is home to a unique multilevel data environment
that enables its researchers to leverage intersections be-
tween informatics, data science, and population science.
Its Research Informatics shared resource offers robust
software solutions that allow our researchers to collect and
mine data from local, state, and national sources, such as
the Utah Cancer Registry, Utah Population Database, tu-
mor registries, Oncology Research Information Exchange
Network (ORIEN), ColoCare, and Flatiron. It uses state-
of-the-art capabilities, including natural language
processing.21 HCI researchers are implementing novel
strategies for identifying and managing individuals with
hereditary cancer through the EHR to facilitate translation
of genetic discoveries to the clinic and population. TheUtah
Population Database (UPDB) is a unique and vital tool for
conducting population-based studies, gene discovery, and
health services research. Data in the UPDB comprise
medical, public, health, and demographic data for 11
million individuals across the span of decades. The UPDB
has been instrumental in the discovery of several key ge-
netic discoveries in cancer, such as BRCA 122 and
CDKN2A.23 In addition, UPDB has been used for research
in cancer survivorship and disease risk quantiﬁcation and
prevention.24,25 The UPDB is also linked to the Utah Cancer
Registry, which is part of the NCI’s SEER program. On
a national scale, HCI has partnered with the ORIEN Net-
work and Flatiron. HCI has used its partnership with Flatiron
to link with data on patient-reported outcomes, assessed in
their clinics at regular intervals, and have used these
patient-reported outcomes as clinical predictors for ad-
vanced cancers. HCI leverages a unique multilevel data
environment and capabilities in state-of-the-art data sci-
ence to advance cancer research and translation of dis-
coveries for maximum impact to the clinic and population.
TOPICS ON THE HORIZON FOR CANCER INFORMATICS
The focus on intersections between population science,
data science, and informatics highlighted several topics
requiring further discussion and dialogue at future CI4CC
meetings, including harmonization of data across existing
common data models, linkage of data across initiatives in
a way that preserves de-identiﬁcation yet facilitates the
assessment of overlap between data sets, and challenges
integrating information back into the EHR to enhance
clinical decisions. More broadly, cancer informatics en-
compasses a wide array of topics around data capture, data
organization, data integration, data visualization, and data
interpretation. Corresponding topics on the horizon for
cancer informatics that the CI4CC organization will be
highlighting at future meetings and through their initiatives
are: AI and ML in oncology, involvement with the ASCO
efforts around CancerLinQ andMinimal Common Oncology
Data Elements (mCODE), precision medicine and learning
health platforms, cancer data sharing, data interoperability
(with a particular focus on the link between -omic data and
the EMR), digital health innovation, andNCI CCSG–focused
shared informatics resources.
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